Monitoring steroid diabetes in kidney disease patients
Official title: A Study on the Influencing Factors of Glucocorticoid Induced Elevated Blood Glucose in Nephrotic Patients
Run by Zhejiang Provincial People's Hospital · NCT06161701 · Data updated 2026-11-12
This study is tracking patients with nephrotic syndrome who are starting steroid treatment to see if they develop high blood sugar and to help manage it early on.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Zhejiang Provincial People's Hospital Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | January 10, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | April 29, 2024 |
| Trial ID | NCT06161701 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with nephrotic syndrome who are beginning glucocorticoid therapy and do not have a history of diabetes.
✕Probably not a fit
Patients with pre-existing diabetes or those unable to comply with blood glucose monitoring will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows patients with nephrotic syndrome who are starting glucocorticoid treatment to monitor for the development of steroid diabetes. It involves regular assessments of blood sugar levels and medication usage over a one-year period. The goal is to identify and intervene in cases of elevated blood sugar promptly to prevent irreversible damage. Patients with pre-existing diabetes or certain other conditions are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to timely identification and management of steroid diabetes in kidney disease patients, improving their overall health outcomes.
How similar studies have gone: While the approach of monitoring steroid diabetes in nephrotic syndrome patients is not widely tested, similar observational studies have shown the importance of early detection in managing diabetes related to steroid use.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus； 2. Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone； Exclusion Criteria: 1. Patients with diabetes； 2. Those who are unable to communicate through language； 3. Uremic patients； 4. Unable to perform blood glucose monitoring and follow-up as required； 5. Those who have used glucocorticoids within the past 3 months and have accumulated a dose of 10mg or more of prednisone； 6. Participated in other clinical studies。
Where it's running
-
Zhejiang provincial people's hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Xiaolan Ye, master
- Email: yexl1120@126.com
- Phone: +86-0571-85893117
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
-
SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome
This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.
-
Atacicept for multiple autoimmune glomerular diseases
This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.
-
Multitarget approach for primary podocytopathies
This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.
-
Follow-up on Rituximab treatment for children's nephrotic syndrome
This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.
-
Investigating the role of a protein in kidney damage related to nephrotic syndrome
This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.